GALT vs HRL · $142.4M cap vs P/E 29, rev $8.96B
Galectin Therapeutics Inc (GALT) versus Hormel Foods Corporation (HRL) — a side-by-side from cached financials, not a winner call.
Galectin Therapeutics Inc (GALT) is a biotechnology company listed on US.
Hormel Foods Corporation (HRL) is a packaged foods company listed on NYSE.
GALT does not have a complete income-statement cache yet.
Latest reported HRL revenue for 2026-07-26 was $8.96B. Net income was $398.8M. Revenue was up 49.4% from 2026-04-26 to 2026-07-26. HRL currently screens at market cap $13.39B and trailing P/E 28.6.
GALT currently screens at market cap $142.4M. HRL currently screens at market cap $13.39B and trailing P/E 28.6.
Not investment advice. Open the GALT and HRL stock pages for the full models.
Not investment advice.